Translational Alzheimer imaging biomarker development

Alzheimer's disease is the most common type of dementia with progressive cognitive impairment. The advances in neuroimaging have enabled early diagnosis of Alzheimer's disease, facilitated the understanding of disease mechanism and the development of therapeutic treatment. Our research focuses on developing novel neuroimaging biomarkers for Alzheimer's disease with translational potential. Using multi-scale imaging (PET, MRI and optoacoustic tomography), we have non-invasively visualized Aβ, tau deposits and neurodegeneration in transgenic mouse lines recapitulating amyloid-β (arcAβ, APP/PS1) or tau pathology (P301L). Our pipeline offers new prospects for in vivo studies into Alzheimer's disease mechanisms in animal models as well as longitudinal monitoring of therapeutic responses targeting at amyloid-β and tau.
 

Forschungskredit, Synapsis foundation, Helmut Horten Stiftung, Jubiläumsstiftung von Swiss Life, Zentrum für Neurowissenschaften Zürich (ZNZ) PhD Grant, UZH Entrepreneur Fellowship, Vontobel Stiftung, Olga Mayenfisch Stiftung, Novartis Foundation, SCAHT Swiss Center for Applied Human Toxicology, SERI Research Partnership Grant, Fondation Gustave et Simone Prévot, EU Joint Programme-Neurodegenerative Disease Research (JPND), Schweizerischer Nationalfonds (SNSF), Stiftung Synapsis Schweiz

PhD Students
Benjamin F. Combes
Cinzia Alessandra Maschio